GB0100658D0 - Crystallisation - resistant aqueous growth hormone formulations - Google Patents

Crystallisation - resistant aqueous growth hormone formulations

Info

Publication number
GB0100658D0
GB0100658D0 GBGB0100658.4A GB0100658A GB0100658D0 GB 0100658 D0 GB0100658 D0 GB 0100658D0 GB 0100658 A GB0100658 A GB 0100658A GB 0100658 D0 GB0100658 D0 GB 0100658D0
Authority
GB
United Kingdom
Prior art keywords
crystallisation
growth hormone
resistant aqueous
aqueous growth
hormone formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB0100658.4A
Other versions
GB2371227A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grandis Biotech GmbH
Original Assignee
Grandis Biotech GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grandis Biotech GmbH filed Critical Grandis Biotech GmbH
Priority to GB0100658A priority Critical patent/GB2371227A/en
Publication of GB0100658D0 publication Critical patent/GB0100658D0/en
Priority to PCT/EP2002/000114 priority patent/WO2002067989A1/en
Publication of GB2371227A publication Critical patent/GB2371227A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
GB0100658A 2001-01-10 2001-01-10 Crystallisation - resistant aqueous growth hormone formulations Withdrawn GB2371227A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB0100658A GB2371227A (en) 2001-01-10 2001-01-10 Crystallisation - resistant aqueous growth hormone formulations
PCT/EP2002/000114 WO2002067989A1 (en) 2001-01-10 2002-01-08 Crystallisation-resistant aqueous growth hormone formulations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0100658A GB2371227A (en) 2001-01-10 2001-01-10 Crystallisation - resistant aqueous growth hormone formulations

Publications (2)

Publication Number Publication Date
GB0100658D0 true GB0100658D0 (en) 2001-02-21
GB2371227A GB2371227A (en) 2002-07-24

Family

ID=9906597

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0100658A Withdrawn GB2371227A (en) 2001-01-10 2001-01-10 Crystallisation - resistant aqueous growth hormone formulations

Country Status (2)

Country Link
GB (1) GB2371227A (en)
WO (1) WO2002067989A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030119734A1 (en) 2001-06-28 2003-06-26 Flink James M. Stable formulation of modified GLP-1
AU2003250915A1 (en) * 2002-07-09 2004-01-23 Sandoz Ag LIQUID FORMULATIONS WITH HIGH CONCENTRATION OF HUMAN GROWTH HORMONE (hgh) COMPRISING 1,2-PROLPYLENE GLYCOL
JP4949828B2 (en) * 2003-03-18 2012-06-13 アレス トレーディング ソシエテ アノニム Stabilization of growth hormone in solution
BRPI0410972C1 (en) 2003-06-03 2021-05-25 Novo Nordisk As method for increasing the shelf life of a pharmaceutical composition, pharmaceutical composition, and method for treating hyperglycemia
JP2007524592A (en) 2003-06-03 2007-08-30 ノボ・ノルデイスク・エー／エス Stabilized pharmaceutical peptide composition
PT3300721T (en) * 2003-11-20 2019-06-06 Novo Nordisk As Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
WO2006024631A2 (en) 2004-08-31 2006-03-09 Novo Nordisk A/S Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
ES2458991T3 (en) 2004-11-12 2014-05-07 Novo Nordisk A/S Stable insulinotropic peptide formulations
KR101337797B1 (en) * 2010-07-14 2013-12-06 한미사이언스 주식회사 A liquid formulation of long acting human growth hormone conjugate
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
JP2016503771A (en) 2012-12-21 2016-02-08 サノフイ Exendin-4 derivative
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201625669A (en) 2014-04-07 2016-07-16 賽諾菲公司 Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
TW201625668A (en) 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
TW201625670A (en) 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (en) 2015-06-05 2017-09-27 Sanofi Sa PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
AR105284A1 (en) 2015-07-10 2017-09-20 Sanofi Sa DERIVATIVES OF EXENDINA-4 AS SPECIFIC DUAL PEPTIDE AGONISTS OF GLP-1 / GLUCAGÓN RECEPTORS
WO2019038412A1 (en) 2017-08-24 2019-02-28 Novo Nordisk A/S Glp-1 compositions and uses thereof
AU2021207313A1 (en) 2020-02-18 2022-07-28 Novo Nordisk A/S Pharmaceutical formulations
CN112494638B (en) * 2020-12-22 2023-12-19 深圳科兴药业有限公司 Human growth hormone injection composition and preparation method thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL79552A0 (en) * 1985-07-30 1986-10-31 Int Minerals & Chem Corp Stabilization of growth promoting hormones
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
SE9201073D0 (en) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab PROTEIN FORMULATION
AU686567C (en) * 1992-07-31 2002-08-08 Genentech Inc. Human growth hormone aqueous formulation
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
JP3723857B2 (en) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 Aqueous pharmaceutical composition containing human growth hormone
ES2300268T3 (en) * 1999-07-12 2008-06-16 Sandoz Ag FORMULATIONS OF GROWTH HORMONES.

Also Published As

Publication number Publication date
WO2002067989A1 (en) 2002-09-06
GB2371227A (en) 2002-07-24

Similar Documents

Publication Publication Date Title
GB0100658D0 (en) Crystallisation - resistant aqueous growth hormone formulations
AU2002342653A8 (en) Modified growth hormone
IL162031A0 (en) Chemically-modified human growth hormone conjugates
EG24074A (en) Formulation
AU3373801A (en) Improved paste formulations
EP1391209A4 (en) Protein formulations
IL161596A0 (en) Pesticidal formulations
IL147253A0 (en) Growth hormone formulations
PL367830A1 (en) Aqueous composition
PL367280A1 (en) Agrochemical formulations
AU1495802A (en) Fungicidal formulation
HUP0402334A3 (en) Modified human growth hormone
GB0106565D0 (en) Growth hormone treatment
GB0125492D0 (en) Formulation
AU2002254882A1 (en) Crystallisation-resistant aqueous growth hormone formulations
GB2377151B (en) Fishing aid
GB0111277D0 (en) Gentle marker
GB0115893D0 (en) Formulations
GB2396812B (en) Formulation
GB2375048B (en) Formulation
GB0116619D0 (en) Formulation
GB9916252D0 (en) Growth hormone formulation
GB0112497D0 (en) Formulation
NZ513664A (en) Long acting formulations
GB0107226D0 (en) Formulations

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)